Yoga for Aromatase Inhibitor-associated Joint Pain
Evaluating Yoga for Aromatase Inhibitor-associated Joint Pain in Women With Breast Cancer: A Pilot Study
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Detaillierte Beschreibung
Studientyp
Studientyp
Einschreibung (Tatsächlich)
Einschreibung
Phase
Phase
- Unzutreffend
Kontakte und Standorte
Studienorte
-
-
Florida
-
Tampa, Florida, Vereinigte Staaten, 33612
- H. Lee Moffitt Cancer Center and Research Institute
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Have been diagnosed with stage 0-III breast cancer
- Have completed local and/or adjuvant breast cancer therapy (with the exception of hormonal therapy) at least one month previously
- Are post-menopausal defined as defined as no menses in the past 12 months
- Are currently prescribed an aromatase inhibitor (AI) medication (anastrozole, letrozole, or exemestane) by a Moffitt-affiliated physician
- Report joint pain that started or worsened after initiation of AI medication
- Report worst pain score > 4 in the preceding week on an 11-point (0-10) numeric rating scale
Exclusion Criteria:
- Have been diagnosed with another form of cancer (except nonmelanoma skin cancer) in the last five years
- Have uncontrolled cardiac disease, pulmonary disease, or infectious disease
- Have physical symptoms or conditions that could make yoga unsafe (i.e., neck injuries, dizziness, shortness of breath, chest pain, or severe nausea)
- Have a body mass index (BMI) > 40 kg/m^2 (based on difficulties severly obese individuals may have with engaging in Iyengar yoga poses)
- Have joint pain attributed to inflammatory arthritic conditions (i.e., rheumatoid arthritis, gout, pseudo-gout) per medical record or patient history
- Had surgery within the past 3 months
- Had injections of medication within the last 3 months to joint(s) currently painful
- Are currently using corticosteroids or opioid medications
- Are currently attending yoga classes
- Do not speak or read standard English
- Are scheduled or are planning to discontinue AI medication in the next 16 weeks
- Do not have sufficient access to the Internet to complete study assessments
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Unterstützende Pflege
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Experimental: Intervention Condition
Questionnaires and yoga classes. Group will attend a series of 90-minute yoga classes twice a week for 12 weeks. |
Participants will be asked to complete a set of questionnaires about their health and well-being on two occasions (baseline and follow-up).
Each set of questionnaires will take about 45 minutes to complete.
Iyengar yoga is a traditional form of Hatha yoga that has been used previously to address quality of life issues in women with breast cancer.
Iyengar yoga classes for 90 minutes twice per week for 12 weeks (total of 24 classes).
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Rate of Study Enrollment
Zeitfenster: 24 months
|
Acceptability of the proposed study to potential participants.
The study will be considered acceptable if 50% or more of eligible participants agree to participate.
|
24 months
|
|
Rate of Study Completion
Zeitfenster: Up to 24 weeks per participant
|
Feasibility of the proposed study assessment and intervention methods.
The study methods will be considered feasible if 70% or more of consented participants complete both the baseline and follow-up assessments and attend an average of 70% or more of scheduled yoga classes.
|
Up to 24 weeks per participant
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Occurrence of Reduced Pain Severity
Zeitfenster: Up to 24 weeks per participant
|
Potential efficacy of the intervention in relieving AI medication-associated joint pain.
The intervention will be considered potentially efficacious in relieving AI medication-associated joint pain if comparisons of pre- and post-intervention means for one or more measures of pain severity yield an effect size >/= 0.3 consistent with pain reduction.
|
Up to 24 weeks per participant
|
|
Occurrence of Relief from Other Side Effects
Zeitfenster: Up to 24 weeks per participant
|
Potential efficacy of the intervention in relieving other reported side effects of AI medication (i.e., fatigue, hot flashes, sleep problems, and depressive symptoms).
The intervention will be considered potentially efficacious in relieving other known side effects if comparisons of pre- and post-intervention means yield an effect size >/= 0.3 consistent with side effect reduction.
|
Up to 24 weeks per participant
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Mitarbeiter
Mitarbeiter
Ermittler
Ermittler
- Hauptermittler: Paul Jacobsen, Ph.D., H. Lee Moffitt Cancer Center and Research Institute
Publikationen und hilfreiche Links
Nützliche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Studienbeginn
Primärer Abschluss (Tatsächlich)
Primärer Abschluss
Studienabschluss (Tatsächlich)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- MCC-17592
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .